Zacks Analyst Blog Highlights: Cypress Bioscience, Inc., Forest

  Zacks Analyst Blog Highlights: Cypress Bioscience, Inc., Forest   Laboratories, Inc., Allied Irish Banks, p.l.c., Baxter International and   Pfizer  Business Wire  CHICAGO -- May 14, 2009 announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cypress Bioscience, Inc. (NASDAQ: CYPB), Forest Laboratories, Inc. (NYSE: FRX), Allied Irish Banks, p.l.c. (NYSE: AIB), Baxter International (NYSE: BAX) and Pfizer (NYSE: PFE).  Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:  Here are highlights from Wednesday’s Analyst Blog:  Cypress Bio Banks on Savella  Cypress Bioscience, Inc. (NASDAQ: CYPB) reported financial results for the first quarter 2009 on May 11, 2009. Total revenues for the quarter were $7.9 million, and consisted primarily of collaborative payments from Savella development partner, Forest Laboratories, Inc. (NYSE: FRX). This was generally in-line with our $8.2 million forecast.  Net loss for the quarter was $9.2 million -- and significantly greater than our expectations -- due to approximately $5.0 million in R&D expense associated with a $3.0 million milestone payment to a licensor, Pierre Fabre, upon NDA approval of Savella and a $2.0 million payment in connection with an asset purchase transaction for a technology to diagnose and monitor Lupus. Earnings per share (EPS) for the first quarter equated to ($0.24). Cypress Bio exited the first quarter with $160.4 million in cash.  Allied Irish Banks Improves  In its first quarter trading update, Allied Irish Banks, p.l.c. (NYSE: AIB) announced that operating profits before bad debt provisions were higher than the year-ago quarter, reflecting strong performance of its Capital Markets and Global Treasury divisions.  However, AIB's other operating divisions are experiencing year-over-year declines in operating profits as loan demand continues weak, current account and deposit funding contract, and net interest margins shrink. The decline in the net interest margin principally reflects highly competitive markets, the low interest-rate environment, and higher wholesale funding costs, partly offset by better margins on lending.  Baxter: More Heparin Problems  Not long after reporting a decent first quarter, Baxter International (NYSE: BAX) has made headlines once again for its heparin product.  A renewed heparin-related scare began over the weekend, with two deaths announced and a third patient suffered complications. The common link between all three patients is the administration of heparin. Initial reports indicate that the pharmaceutical ingredients were sourced in North America, likely from Pfizer (NYSE: PFE). The contaminant from the Chinese factory during the 2008 scare (over-sulfated chondroitin sulfate) was not found in the recently tested samples.  Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:  About Zacks Equity Research  Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.  Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.  Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:  About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at  Visit for information about the performance numbers displayed in this press release.  Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.  Contact: Mark Vickery Web Content Editor 312-265-9380 Visit:  
Press spacebar to pause and continue. Press esc to stop.